Inflammatory marker levels and prediction of patient-reported symptoms in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy

被引：0
|
作者：
Wang, Xin Shelley
Shi, Qiuling
Li, Donghui
Eng, Cathy
Bokhari, Raza H.
Fogelman, David R.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e20699
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20699
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer
    de Jesus, Victor H. F.
    Camandaroba, Marcos P. G.
    Calsavara, Vinicius F.
    Riechelmann, Rachel P.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [32] Pancreatic Proteolytic Enzyme Therapy Compared With Gemcitabine-Based Chemotherapy for the Treatment of Pancreatic Cancer
    Chabot, John A.
    Tsai, Wei-Yann
    Fine, Robert L.
    Chen, Chunxia
    Kumah, Carolyn K.
    Antman, Karen A.
    Grann, Victor R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2058 - 2063
  • [33] Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy
    Faruk Tas
    Senem Karabulut
    Rumeysa Ciftci
    Fatma Sen
    Burak Sakar
    Rian Disci
    Derya Duranyildiz
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 1163 - 1171
  • [34] Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy
    Fujita, Hayato
    Ohuchida, Kenoki
    Mizumoto, Kazuhiro
    Itaba, Soichi
    Ito, Tetsuhide
    Nakata, Kohei
    Yu, Jun
    Kayashima, Tadashi
    Souzaki, Ryota
    Tajiri, Tatsuro
    Manabe, Tatsuya
    Ohtsuka, Takao
    Tanaka, Masao
    NEOPLASIA, 2010, 12 (10): : 807 - U161
  • [35] Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy
    Tas, Faruk
    Karabulut, Senem
    Ciftci, Rumeysa
    Sen, Fatma
    Sakar, Burak
    Disci, Rian
    Duranyildiz, Derya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (06) : 1163 - 1171
  • [36] Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy
    Kouzy, Ramez
    Jaoude, Joseph Abi
    Lin, Daniel
    Nguyen, Nicholas D.
    El Alam, Molly B.
    Ludmir, Ethan B.
    Taniguchi, Cullen M.
    CANCERS, 2020, 12 (09) : 1 - 15
  • [37] Overall Survival of Patients with Advanced Pancreatic Cancer Improved with an Increase in Second-Line Chemotherapy after Gemcitabine-Based Therapy
    Zhang, Yuan-Dong
    Yang, Qiong
    Jiang, Zhi-min
    Ma, Wen
    Zhou, Si-wei
    Xie, De-rong
    JOURNAL OF THE PANCREAS, 2011, 12 (02): : 131 - 137
  • [38] HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients
    Richards, Nathan G.
    Rittenhouse, David W.
    Freydin, Boris
    Cozzitorto, Joseph A.
    Grenda, Dane
    Rui, Hallgeir
    Gonye, Greg
    Kennedy, Eugene P.
    Yeo, Charles J.
    Brody, Jonathan R.
    Witkiewicz, Agnieszka K.
    ANNALS OF SURGERY, 2010, 252 (03) : 499 - 506
  • [39] A PATIENT WITH UNRESECTABLE ADVACED PANCREATIC CANCER ACHIEVING LONG-TERM SURVIVAL WITH GEMCITABINE-BASED CHEMOTHERAPY
    Lotesoriere, C.
    Perrucci, B.
    Montrone, M.
    Bruno, M.
    Russo, F.
    Pisconti, S.
    CANCER TREATMENT REVIEWS, 2010, 36 : S97 - S97
  • [40] A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
    Kanai, Masashi
    Yoshimura, Kenichi
    Asada, Masanori
    Imaizumi, Atsushi
    Suzuki, Chihiro
    Matsumoto, Shigemi
    Nishimura, Takafumi
    Mori, Yukiko
    Masui, Toshihiko
    Kawaguchi, Yoshiya
    Yanagihara, Kazuhiro
    Yazumi, Shujiro
    Chiba, Tsutomu
    Guha, Sushovan
    Aggarwal, Bharat B.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (01) : 157 - 164
12345